Outpatient Antibiotic Resistance Patterns of Escherichia coli Urinary Isolates Differ by Specialty Type.
Ampicillin
Anti-Bacterial Agents
/ pharmacology
Child
Ciprofloxacin
/ pharmacology
Drug Resistance, Bacterial
Drug Resistance, Microbial
Escherichia coli
Escherichia coli Infections
/ drug therapy
Gentamicins
Humans
Microbial Sensitivity Tests
Outpatients
Trimethoprim, Sulfamethoxazole Drug Combination
/ pharmacology
Urinary Tract Infections
/ drug therapy
E. coli
UTI
antimicrobial resistance
outpatient
specialty
Journal
Microbiology spectrum
ISSN: 2165-0497
Titre abrégé: Microbiol Spectr
Pays: United States
ID NLM: 101634614
Informations de publication
Date de publication:
31 08 2022
31 08 2022
Historique:
pubmed:
22
6
2022
medline:
9
9
2022
entrez:
21
6
2022
Statut:
ppublish
Résumé
Antibiotic-resistant E. coli infections represent a major cause of morbidity and mortality and pose a challenge to antibiotic stewardship. We analyzed a large outpatient data set of E. coli urinary isolates to determine whether resistance patterns vary between types of outpatient practices. Using deidentified data from a clinical reference laboratory over 5 years and logistic regression, we examined the association of antibiotic resistance with outpatient practice type, controlling for testing year, patient sex, and patient age. The odds of antibiotic resistance were significantly higher in urology/nephrology practices for ampicillin (odds ratio [OR] 1.36; 95% CI, 1.10 to 1.69), ciprofloxacin (OR 2.29; 95% CI, 1.77 to 2.94), trimethoprim-sulfamethoxazole (OR 1.52; 95% CI, 1.18 to 1.94), and gentamicin (OR 1.72; 95% CI, 1.16 to 2.46). Odds of resistance were also higher for ciprofloxacin in oncology practices (OR 1.54; 95% CI, 1.08 to 2.15) and "all other specialties" (OR 1.33; 95% CI, 1.13 to 1.56). In contrast, specimens from obstetrics and gynecology practices had lower odds of having resistance to ampicillin (OR 0.90; 95% CI, 0.82 to 0.99) and trimethoprim-sulfa (OR 0.83; 95% CI, 0.73 to 0.93) but higher odds of having resistance to nitrofurantoin (OR 1.33; 95% CI, 1.03 to 1.70). Other findings included lower odds of having resistance to trimethoprim-sulfa in pediatric practices (OR 0.78; 95% CI, 0.64 to 0.94) and lower odds of having resistance to gentamicin in isolates from internal medicine practices (OR 0.66; 95% CI, 0.51 to 0.84) (all
Identifiants
pubmed: 35727039
doi: 10.1128/spectrum.02373-21
pmc: PMC9431218
doi:
Substances chimiques
Anti-Bacterial Agents
0
Gentamicins
0
Ciprofloxacin
5E8K9I0O4U
Ampicillin
7C782967RD
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0237321Références
J Antimicrob Chemother. 2013 Mar;68(3):715-8
pubmed: 23148204
Clin Infect Dis. 2012 Sep;55(5):687-94
pubmed: 22752512
J Antimicrob Chemother. 2006 Dec;58(6):1303-6
pubmed: 17062608
Clin Infect Dis. 2016 Aug 15;63(4):443-9
pubmed: 27199462
Am J Med. 2002 Jul 8;113 Suppl 1A:5S-13S
pubmed: 12113866
J Clin Microbiol. 2021 Nov 18;59(12):e0021321
pubmed: 34550809
MMWR Morb Mortal Wkly Rep. 2018 Jan 12;67(1):18-22
pubmed: 29324733
Obstet Gynecol. 2011 Jun;117(6):1484-1485
pubmed: 21606771
J Urol. 2005 Apr;173(4):1281-7
pubmed: 15758783
Infect Control Hosp Epidemiol. 2021 Dec;42(12):1437-1444
pubmed: 33622432
Clin Infect Dis. 2021 Sep 15;73(6):1066-1074
pubmed: 33768228
BMC Med. 2014 Jun 11;12:96
pubmed: 24916809
J Urol. 2019 Aug;202(2):282-289
pubmed: 31042112
Clin Infect Dis. 2011 Mar 1;52(5):e103-20
pubmed: 21292654
Infect Chemother. 2018 Mar;50(1):67-100
pubmed: 29637759
J Antimicrob Chemother. 2017 Jan;72(1):281-289
pubmed: 27655855